Marvell partners with Mojo Vision for micro-LED data center solutions

Marvell Technology Inc. (NASDAQ: MRVL) announced a collaboration with micro-LED platform company Mojo Vision to develop optical interconnect solutions for AI data center infrastructure, according to a company statement.

The partnership includes Marvell's investment as the largest participant in Mojo Vision's 2025 Series B Prime financing round. The companies entered a multi-generational agreement to jointly develop micro-LED connectivity products that have been under development for over a year.

The optical interconnects integrate electrical circuitry, micro-LED emitters, photodetectors, fiber bundles and software into a single architecture designed to move terabits of data per millimeter at low power consumption over short distances.

"Micro-LED technology represents an important technology capability for high-performance data center connectivity applications," said Xi Wang, senior vice president and general manager of Marvell's Connectivity Business Unit.

Mojo Vision CEO Nikhil Balram stated the company's design "enables thousands of optical lanes in a tiny footprint—about the size of a grain of sand—delivering orders-of-magnitude bandwidth gains while significantly reducing energy per bit."

The solutions target hyperscale and cloud data center customers seeking to connect arrays of processing units and shared memory pools for distributed computing architectures. The micro-LED arrays include pixel-level redundancy and dynamic mapping capabilities for reliability.

Vladimir Kozlov, founder and CEO of LightCounting, noted that hyperscalers are seeking optical technologies that address performance, manufacturability, reliability and cost requirements simultaneously.

The collaboration aims to support various AI data center interconnect form factors and applications as demand grows for higher bandwidth density and lower power consumption in data center infrastructure.

You May Also Be Interested In

• Michael Burry Says He Shorted Caterpillar For The First Time - Bloomberg
• Amarin highlights Vascepa cost advantage over new injectable rivals
• Corey Goodman resigns as ALX Oncology board chairman